Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

(2019) Hiddo J L Heerspink et al.   LANCET

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

(2019) Jeroen V. Koomen et al.   DIABETES OBESITY & METABOLISM

Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy

(2018) Chih-Wei Lin et al.   CLINICAL THERAPEUTICS

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

(2018) Hiddo J. L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight

(2018) Jeroen V. Koomen et al.   DIABETES OBESITY & METABOLISM

Baseline characteristics and enrichment results from the SONAR trial

(2018) Hiddo J.L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

(2017) David J. Webb et al.   Drugs in research & development

Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy

(2015) D. E. Kohan et al.   Clinical Journal of the American Society of Nephrology

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

(2014) D. de Zeeuw et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy

(2011) D. E. Kohan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Endothelin, hypertension and chronic kidney disease: new insights

(2010) Donald E Kohan   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Avosentan for Overt Diabetic Nephropathy

(2010) J. F.E. Mann et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Likelihood based approaches to handling data below the quantification limit using NONMEM VI

(2008) Jae Eun Ahn et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS